Posts in Uncategorized

The EURD List and PSUSA: How Union Reference Dates Decide Your PSUR Obligations

For most marketing authorisation holders, the question of when a periodic safety update report is due is not answered by the marketing authorisation itself. It[…]

High-Cost Medicines Through Private Pharmacies in Greece: What the New EOPYY Model Means for Manufacturers

Since 5 February 2026, patients in Greece receiving certain high-cost medicines have been able to collect them from a private community pharmacy of their choice,[…]

US Most-Favoured-Nation Pricing and European Launches: What It Means for Market Access in Greece

Since the White House’s May 2025 executive order on most-favoured-nation (MFN) pricing, US drug prices have become increasingly linked to prices paid in other high-income[…]

Annex 11 and Annex 22 in Late 2026: What to Settle Now While the Final Texts Are Pending

More than a year after the consultation closed, the revised EU GMP Annex 11 on computerised systems and the new Annex 22 on artificial intelligence[…]

Continuous Compliance Monitoring for SaaS GxP Systems: Keeping Validation Current Through Every Vendor Release

Cloud and software-as-a-service platforms now run quality management, pharmacovigilance, regulatory information and laboratory processes across the industry. They also change on the vendor’s schedule, often[…]

FDA’s Final PDURS Guidance: When a Companion App Becomes Drug Labelling

In October 2026, the US Food and Drug Administration finalised its guidance on Prescription Drug Use-Related Software (PDURS), three years after the 2023 draft. It[…]

ICH M15 on Model-Informed Drug Development: How Regulators Will Judge Your Models

Modelling and simulation now support dose selection, paediatric extrapolation, drug interaction claims and trial design across most development programmes. ICH M15, adopted at Step 4[…]

ICH Q3E on Extractables and Leachables: Preparing for the First Harmonised E&L Guideline

Extractables and leachables have long been assessed through a patchwork of regional guidance, pharmacopoeial chapters and industry practice. ICH Q3E is set to become the[…]

ICH E6(R3) Annex 2: Good Clinical Practice for Decentralised, Pragmatic and Real-World Data Trials

ICH finalised Annex 2 to the E6(R3) Good Clinical Practice guideline on 3 June 2026. Where the core E6(R3) principles and Annex 1 describe GCP[…]

eCTD 4.0 Forward Compatibility: What the FDA’s October 2026 Notice Means for EU and US Submissions

On 16 October 2026, the US Food and Drug Administration announced that CDER and CBER will accept eCTD v4.0 submissions to applications that were originally[…]

1 2 3 … 26